APO Research
Talk to an analyst

APO RESEARCH · REPORT

Selective Serotonin Reuptake Inhibitors (SSRIs)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Analysis and Forecast 2026-2032

22 December 2025199 pages

Choose your research edition.

Industry ResearchSelective Serotonin Reuptake Inhibitors (SSRIs) Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Selective Serotonin Reuptake Inhibitors (SSRIs) Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Selective Serotonin Reuptake Inhibitors (SSRIs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Selective Serotonin Reuptake Inhibitors (SSRIs) Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Selective Serotonin Reuptake Inhibitors (SSRIs) Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Selective Serotonin Reuptake Inhibitors (SSRIs) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Selective Serotonin Reuptake Inhibitors (SSRIs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Selective Serotonin Reuptake Inhibitors (SSRIs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Selective Serotonin Reuptake Inhibitors (SSRIs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Selective Serotonin Reuptake Inhibitors (SSRIs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Selective Serotonin Reuptake Inhibitors (SSRIs) include Allergan Plc, H. Lundbeck AS, GlaxoSmithKline Plc, Pfizer Inc. and Eli Lilly and Co., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Selective Serotonin Reuptake Inhibitors (SSRIs), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Selective Serotonin Reuptake Inhibitors (SSRIs), also provides the revenue of main regions and countries. Of the upcoming market potential for Selective Serotonin Reuptake Inhibitors (SSRIs), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Selective Serotonin Reuptake Inhibitors (SSRIs) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Selective Serotonin Reuptake Inhibitors (SSRIs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Selective Serotonin Reuptake Inhibitors (SSRIs) revenue, projected growth trends, production technology, application and end-user industry.

Selective Serotonin Reuptake Inhibitors (SSRIs) Segment by Company

Allergan Plc

H. Lundbeck AS

GlaxoSmithKline Plc

Pfizer Inc.

Eli Lilly and Co.

Selective Serotonin Reuptake Inhibitors (SSRIs) Segment by Type

Citalopram (Celexa)

Sertraline (Zoloft)

Paroxetine (Paxil, Pexeva)

Fluoxetine (Prozac)

Vilazodone (Viibryd)

Escitalopram (Lexapro)

Selective Serotonin Reuptake Inhibitors (SSRIs) Segment by Application

Depression

Other mental conditions

Anxiety and panic disorder

Selective Serotonin Reuptake Inhibitors (SSRIs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Selective Serotonin Reuptake Inhibitors (SSRIs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Selective Serotonin Reuptake Inhibitors (SSRIs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Selective Serotonin Reuptake Inhibitors (SSRIs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Selective Serotonin Reuptake Inhibitors (SSRIs) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Selective Serotonin Reuptake Inhibitors (SSRIs) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Selective Serotonin Reuptake Inhibitors (SSRIs) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Citalopram (Celexa) Major Player Table 3. Sertraline (Zoloft) Major Player Table 4. Paroxetine (Paxil, Pexeva) Major Player Table 5. Fluoxetine (Prozac) Major Player Table 6. Vilazodone (Viibryd) Major Player Table 7. Escitalopram (Lexapro) Major Player Table 8. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Depression Major Player Table 10. Other mental conditions Major Player Table 11. Anxiety and panic disorder Major Player Table 12. Selective Serotonin Reuptake Inhibitors (SSRIs) Industry Trends Table 13. Selective Serotonin Reuptake Inhibitors (SSRIs) Industry Drivers Table 14. Selective Serotonin Reuptake Inhibitors (SSRIs) Industry Opportunities and Challenges Table 15. Selective Serotonin Reuptake Inhibitors (SSRIs) Industry Restraints Table 16. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Share by Region (2021-2026) Table 19. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Share by Region (2027-2032) Table 21. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share by Players (2021-2026) Table 23. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Key Players Headquarters & Area Served Table 25. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Players, Product Type & Application Table 26. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Selective Serotonin Reuptake Inhibitors (SSRIs) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share by Type (2021-2026) Table 33. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share by Type (2027-2032) Table 34. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share by Application (2021-2026) Table 38. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share by Application (2027-2032) Table 39. Allergan Plc Company Information Table 40. Allergan Plc Business Overview Table 41. Allergan Plc Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Allergan Plc Selective Serotonin Reuptake Inhibitors (SSRIs) Product Portfolio Table 43. Allergan Plc Recent Development Table 44. H. Lundbeck AS Company Information Table 45. H. Lundbeck AS Business Overview Table 46. H. Lundbeck AS Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. H. Lundbeck AS Selective Serotonin Reuptake Inhibitors (SSRIs) Product Portfolio Table 48. H. Lundbeck AS Recent Development Table 49. GlaxoSmithKline Plc Company Information Table 50. GlaxoSmithKline Plc Business Overview Table 51. GlaxoSmithKline Plc Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. GlaxoSmithKline Plc Selective Serotonin Reuptake Inhibitors (SSRIs) Product Portfolio Table 53. GlaxoSmithKline Plc Recent Development Table 54. Pfizer Inc. Company Information Table 55. Pfizer Inc. Business Overview Table 56. Pfizer Inc. Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Pfizer Inc. Selective Serotonin Reuptake Inhibitors (SSRIs) Product Portfolio Table 58. Pfizer Inc. Recent Development Table 59. Eli Lilly and Co. Company Information Table 60. Eli Lilly and Co. Business Overview Table 61. Eli Lilly and Co. Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Eli Lilly and Co. Selective Serotonin Reuptake Inhibitors (SSRIs) Product Portfolio Table 63. Eli Lilly and Co. Recent Development Table 64. North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2026) & (US$ Million) Table 65. North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2027-2032) & (US$ Million) Table 66. North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2026) & (US$ Million) Table 67. North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2027-2032) & (US$ Million) Table 68. North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 69. North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2021-2026) & (US$ Million) Table 70. North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (US$ Million) & (2027-2032) Table 71. Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2026) & (US$ Million) Table 72. Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2027-2032) & (US$ Million) Table 73. Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2026) & (US$ Million) Table 74. Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2027-2032) & (US$ Million) Table 75. Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 76. Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2021-2026) & (US$ Million) Table 77. Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (US$ Million) & (2027-2032) Table 78. China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2026) & (US$ Million) Table 79. China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2027-2032) & (US$ Million) Table 80. China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2026) & (US$ Million) Table 81. China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2027-2032) & (US$ Million) Table 82. Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2026) & (US$ Million) Table 83. Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2027-2032) & (US$ Million) Table 84. Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2026) & (US$ Million) Table 85. Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2027-2032) & (US$ Million) Table 86. Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 87. Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Region (US$ Million) & (2021-2026) Table 88. Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Region (US$ Million) & (2027-2032) Table 89. SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2026) & (US$ Million) Table 90. SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2027-2032) & (US$ Million) Table 91. SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2026) & (US$ Million) Table 92. SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2027-2032) & (US$ Million) Table 93. SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 94. SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2021-2026) & (US$ Million) Table 95. SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (US$ Million) & (2027-2032) Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. Selective Serotonin Reuptake Inhibitors (SSRIs) Image Figure 2. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Citalopram (Celexa) Image Figure 5. Sertraline (Zoloft) Image Figure 6. Paroxetine (Paxil, Pexeva) Image Figure 7. Fluoxetine (Prozac) Image Figure 8. Vilazodone (Viibryd) Image Figure 9. Escitalopram (Lexapro) Image Figure 10. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Share 2021 VS 2025 VS 2032 Figure 12. Depression Image Figure 13. Other mental conditions Image Figure 14. Anxiety and panic disorder Image Figure 15. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size (US$ Million) & (2021-2032) Figure 16. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share by Type (2021-2032) Figure 23. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share by Application (2021-2032) Figure 26. North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Type (2021-2032) Figure 28. North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Application (2021-2032) Figure 29. North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Country (2021-2032) Figure 30. United States Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Type (2021-2032) Figure 35. Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Application (2021-2032) Figure 36. Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Country (2021-2032) Figure 37. Germany Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Type (2021-2032) Figure 47. China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Application (2021-2032) Figure 48. Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Type (2021-2032) Figure 50. Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Application (2021-2032) Figure 51. Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Region (2021-2032) Figure 52. Japan Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Type (2021-2032) Figure 60. SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Application (2021-2032) Figure 61. SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Country (2021-2032) Figure 62. Brazil Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Citalopram (Celexa)
  • Sertraline (Zoloft)
  • Paroxetine (Paxil, Pexeva)
  • Fluoxetine (Prozac)
  • Vilazodone (Viibryd)
  • Escitalopram (Lexapro)
Applications
  • Depression
  • Other mental conditions
  • Anxiety and panic disorder
Companies covered
  • Allergan Plc
  • H. Lundbeck AS
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Eli Lilly and Co.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Market by Type
  3. 1.2.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Citalopram (Celexa)
  5. 1.2.3 Sertraline (Zoloft)
  6. 1.2.4 Paroxetine (Paxil, Pexeva)
  7. 1.2.5 Fluoxetine (Prozac)
  8. 1.2.6 Vilazodone (Viibryd)
  9. 1.2.7 Escitalopram (Lexapro)
  10. 1.3 Selective Serotonin Reuptake Inhibitors (SSRIs) Market by Application
  11. 1.3.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Depression
  13. 1.3.3 Other mental conditions
  14. 1.3.4 Anxiety and panic disorder
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Dynamics
  1. 2.1 Selective Serotonin Reuptake Inhibitors (SSRIs) Industry Trends
  2. 2.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Industry Drivers
  3. 2.3 Selective Serotonin Reuptake Inhibitors (SSRIs) Industry Opportunities and Challenges
  4. 2.4 Selective Serotonin Reuptake Inhibitors (SSRIs) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Perspective (2021-2032)
  2. 3.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Growth Trends by Region
  3. 3.2.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Region (2021-2026)
  5. 3.2.3 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Players
  2. 4.1.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Players (2021-2026)
  3. 4.1.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Key Players Headquarters & Area Served
  7. 4.4 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Players, Product Type & Application
  8. 4.5 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market CR5 and HHI
  11. 4.6.3 2025 Selective Serotonin Reuptake Inhibitors (SSRIs) Tier 1, Tier 2, and Tier 3
5 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Type
  1. 5.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2032)
  3. 5.3 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share by Type (2021-2032)
6 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Application
  1. 6.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2032)
  3. 6.3 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Allergan Plc
  2. 7.1.1 Allergan Plc Company Information
  3. 7.1.2 Allergan Plc Business Overview
  4. 7.1.3 Allergan Plc Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Allergan Plc Selective Serotonin Reuptake Inhibitors (SSRIs) Product Portfolio
  6. 7.1.5 Allergan Plc Recent Developments
  7. 7.2 H. Lundbeck AS
  8. 7.2.1 H. Lundbeck AS Company Information
  9. 7.2.2 H. Lundbeck AS Business Overview
  10. 7.2.3 H. Lundbeck AS Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 H. Lundbeck AS Selective Serotonin Reuptake Inhibitors (SSRIs) Product Portfolio
  12. 7.2.5 H. Lundbeck AS Recent Developments
  13. 7.3 GlaxoSmithKline Plc
  14. 7.3.1 GlaxoSmithKline Plc Company Information
  15. 7.3.2 GlaxoSmithKline Plc Business Overview
  16. 7.3.3 GlaxoSmithKline Plc Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 GlaxoSmithKline Plc Selective Serotonin Reuptake Inhibitors (SSRIs) Product Portfolio
  18. 7.3.5 GlaxoSmithKline Plc Recent Developments
  19. 7.4 Pfizer Inc.
  20. 7.4.1 Pfizer Inc. Company Information
  21. 7.4.2 Pfizer Inc. Business Overview
  22. 7.4.3 Pfizer Inc. Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Inc. Selective Serotonin Reuptake Inhibitors (SSRIs) Product Portfolio
  24. 7.4.5 Pfizer Inc. Recent Developments
  25. 7.5 Eli Lilly and Co.
  26. 7.5.1 Eli Lilly and Co. Company Information
  27. 7.5.2 Eli Lilly and Co. Business Overview
  28. 7.5.3 Eli Lilly and Co. Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Eli Lilly and Co. Selective Serotonin Reuptake Inhibitors (SSRIs) Product Portfolio
  30. 7.5.5 Eli Lilly and Co. Recent Developments
8 North America
  1. 8.1 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue (2021-2032)
  2. 8.2 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2032)
  3. 8.2.1 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2026)
  4. 8.2.2 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2027-2032)
  5. 8.3 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Type (2021-2032)
  6. 8.4 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2032)
  7. 8.4.1 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2026)
  8. 8.4.2 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2027-2032)
  9. 8.5 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Application (2021-2032)
  10. 8.6 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country
  11. 8.6.1 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2021-2026)
  13. 8.6.3 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue (2021-2032)
  2. 9.2 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2027-2032)
  5. 9.3 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2027-2032)
  9. 9.5 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country
  11. 9.6.1 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue (2021-2032)
  2. 10.2 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2032)
  3. 10.2.1 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2026)
  4. 10.2.2 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2027-2032)
  5. 10.3 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Type (2021-2032)
  6. 10.4 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2032)
  7. 10.4.1 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2026)
  8. 10.4.2 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2027-2032)
  9. 10.5 China Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue (2021-2032)
  2. 11.2 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2027-2032)
  5. 11.3 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2027-2032)
  9. 11.5 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country
  11. 11.6.1 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue (2021-2032)
  2. 12.2 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country
  11. 12.6.1 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst